UFP Technologies (UFPT) | Financial Analysis & Statements
UFP Technologies Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
148.9M
Gross Profit
42.0M
28.18%
Operating Income
21.0M
14.10%
Net Income
17.6M
11.80%
Balance Sheet Metrics
Total Assets
655.1M
Total Liabilities
231.2M
Shareholders Equity
423.9M
Debt to Equity
0.55
Cash Flow Metrics
Operating Cash Flow
26.1M
Free Cash Flow
13.0M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
UFP Technologies Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 602.8M | 504.4M | 400.1M | 353.8M | 206.3M |
| Cost of Goods Sold | 432.4M | 357.7M | 287.8M | 263.5M | 155.2M |
| Gross Profit | 170.4M | 146.7M | 112.2M | 90.3M | 51.1M |
| Gross Margin % | 28.3% | 29.1% | 28.1% | 25.5% | 24.8% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 77.4M | 62.2M | 50.9M | 45.8M | 29.5M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 77.4M | 62.2M | 50.9M | 45.8M | 29.5M |
| Operating Income | 93.0M | 84.5M | 61.3M | 44.5M | 21.6M |
| Operating Margin % | 15.4% | 16.7% | 15.3% | 12.6% | 10.5% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | 49.0K |
| Interest Expense | 9.8M | 8.1M | 3.6M | 2.8M | 39.0K |
| Other Non-Operating Income | -654.0K | -3.4M | -3.8M | 11.0M | -390.0K |
| Pre-tax Income | 82.5M | 73.0M | 53.9M | 52.7M | 21.2M |
| Income Tax | 14.2M | 14.0M | 9.0M | 10.9M | 5.3M |
| Effective Tax Rate % | 17.2% | 19.2% | 16.7% | 20.7% | 25.1% |
| Net Income | 68.3M | 59.0M | 44.9M | 41.8M | 15.9M |
| Net Margin % | 11.3% | 11.7% | 11.2% | 11.8% | 7.7% |
| Key Metrics | |||||
| EBITDA | 112.1M | 99.4M | 72.6M | 56.4M | 30.1M |
| EPS (Basic) | $8.87 | $7.69 | $5.89 | $5.52 | $2.11 |
| EPS (Diluted) | $8.75 | $7.58 | $5.83 | $5.45 | $2.09 |
| Basic Shares Outstanding | 7705000 | 7668000 | 7624000 | 7564000 | 7524000 |
| Diluted Shares Outstanding | 7705000 | 7668000 | 7624000 | 7564000 | 7524000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
UFP Technologies Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 20.3M | 13.4M | 5.3M | 4.5M | 11.1M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 82.9M | 84.7M | 64.4M | 55.1M | 39.4M |
| Inventory | 86.9M | 87.5M | 70.2M | 53.5M | 33.4M |
| Other Current Assets | - | - | - | - | - |
| Total Current Assets | 201.0M | 194.9M | 144.6M | 116.3M | 87.3M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 18.9M | 16.1M | 13.6M | 13.2M | 9.3M |
| Goodwill | 535.7M | 523.6M | 290.6M | 294.4M | 283.4M |
| Intangible Assets | 140.8M | 144.3M | 64.1M | 68.4M | 67.6M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 10.9M | 6.6M | 6.4M | 9.2M | 5.4M |
| Total Non-Current Assets | 454.1M | 434.0M | 259.5M | 261.8M | 246.8M |
| Total Assets | 655.1M | 629.0M | 404.1M | 378.2M | 334.1M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 24.3M | 24.3M | 22.3M | 20.0M | 10.6M |
| Short-term Debt | 17.5M | 16.7M | 7.2M | 6.5M | 6.2M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | 6.9M | 4.7M |
| Total Current Liabilities | 74.9M | 76.3M | 58.2M | 56.0M | 38.8M |
| Non-Current Liabilities | |||||
| Long-term Debt | 136.9M | 189.3M | 38.8M | 61.9M | 78.1M |
| Deferred Tax Liabilities | 9.2M | 3.3M | 428.0K | 448.0K | 3.3M |
| Other Non-Current Liabilities | 3.5M | 6.2M | 7.1M | 8.7M | 15.2M |
| Total Non-Current Liabilities | 156.3M | 209.9M | 59.8M | 84.7M | 100.9M |
| Total Liabilities | 231.2M | 286.2M | 118.0M | 140.6M | 139.7M |
| Equity | |||||
| Common Stock | 77.0K | 77.0K | 76.0K | 76.0K | 75.0K |
| Retained Earnings | 374.8M | 306.5M | 247.5M | 202.6M | 160.8M |
| Treasury Stock | 587.0K | 587.0K | 587.0K | 587.0K | 587.0K |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 423.9M | 342.8M | 286.1M | 237.5M | 194.4M |
| Key Metrics | |||||
| Total Debt | 154.5M | 206.0M | 46.0M | 68.4M | 84.4M |
| Working Capital | 126.1M | 118.6M | 86.4M | 60.4M | 48.5M |
Balance Sheet Composition
UFP Technologies Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 68.3M | 59.0M | 44.9M | 41.8M | 15.9M |
| Depreciation & Amortization | 19.2M | 14.7M | 11.4M | 11.9M | 8.4M |
| Stock-Based Compensation | 8.9M | 6.8M | 4.6M | 3.2M | 2.4M |
| Working Capital Changes | -5.2M | -15.9M | -23.2M | -32.2M | -11.1M |
| Operating Cash Flow | 96.4M | 66.9M | 42.1M | 29.8M | 13.9M |
| Investing Activities | |||||
| Capital Expenditures | -12.9M | -9.6M | -10.5M | 21.9M | -5.3M |
| Acquisitions | -14.7M | -197.5M | 0 | -20.7M | -96.2M |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -27.6M | -207.1M | -10.5M | 1.3M | -101.5M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 68.7M | 284.2M | 0 | 0 | 40.0M |
| Debt Repayment | -122.7M | -126.9M | -32.1M | -64.1M | -29.0K |
| Financing Cash Flow | -58.4M | 152.2M | -30.7M | -26.3M | 73.9M |
| Free Cash Flow | 79.0M | 56.9M | 30.8M | 4.0M | 8.9M |
| Net Change in Cash | 10.5M | 12.0M | 906.0K | 4.8M | -13.7M |
Cash Flow Trend
UFP Technologies Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
22.64
Forward P/E
17.30
Price to Book
3.60
Price to Sales
2.53
PEG Ratio
3.21
Profitability Ratios
Profit Margin
11.33%
Operating Margin
14.10%
Return on Equity
17.82%
Return on Assets
9.05%
Financial Health
Current Ratio
2.68
Debt to Equity
36.45
Beta
1.17
Per Share Data
EPS (TTM)
$8.75
Book Value per Share
$54.95
Revenue per Share
$78.24
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| UFPT | 1.5B | 22.64 | 3.60 | 17.82% | 11.33% | 36.45 |
| Abbott Laboratories | 160.7B | 25.97 | 3.09 | 12.36% | 13.90% | 26.79 |
| Stryker | 126.3B | 39.21 | 5.62 | 15.08% | 12.92% | 72.97 |
| Axogen | 1.9B | -110.18 | 13.15 | -13.49% | -6.97% | 55.50 |
| Establishment Labs | 1.9B | -37.89 | 79.68 | -133.25% | -24.19% | 1,123.15 |
| Artivion | 1.8B | 179.71 | 4.03 | 2.70% | 2.21% | 57.67 |
Financial data is updated regularly. All figures are in the company's reporting currency.






